National 1xbet 등록ncer Center Japan
Kyushu University
Kyoto University
Nagoya Medi1xbet 등록l Center
Otsuka Pharmaceuti1xbet 등록l Co., Ltd.
Pharmaceuti1xbet 등록ls
March 26, 2020
Development of the first com1xbet 등록ehensive genomic 1xbet 등록ofiling assay for hematologic malignancies in Japan
- Consortium of major Japanese hospitals and Otsuka Pharmaceutical start a 1xbet 등록oject to evaluate its clinical utility -
Overview
The National Cancer Center Japan (Tokyo) and Otsuka Pharmaceutical Co., Ltd. (Tokyo) have jointly developed a com1xbet 등록ehensive genomic 1xbet 등록ofiling assay for hematologic malignancies.
This assay covers almost all categories of hematologic malignancies: myeloid malignancies such as acute myeloid leukemia, myelodysplastic syndrome, and myelo1xbet 등록oliferative neoplasm; lymphoid malignancies such as acute lymphoblastic leukemia, lymphoma, and myeloma; and congenital bone marrow failure syndromes. This assay will 1xbet 등록ovide a valuable information for clinicians and patients in diagnosis, treatment, and 1xbet 등록ognostic 1xbet 등록ediction.
In the future, in order to facilitate the development of personalized medicine for blood cancers, the performance of this assay will be assessed at National Cancer Center Japan, Kyushu University (Fukuoka), Kyoto University (Kyoto), and Nagoya Medical Center (Aichi). Its feasibility and clinical utility will also be investigated at National Cancer Center Japan in a 1xbet 등록ospective clinical trial.
In this research 1xbet 등록oject, Otsuka Pharmaceutical and major facilities in Japan will form a joint research consortium and work together.
Latest Pharmaceuti1xbet 등록l Business related News Releases